LAVA Therapeutics N.V.

    LAVA Therapeutics N.V.

    NNASDAQ:LVTX
    1.74
    USD
    0.00
    (0.00%)
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    0.15
    0.27
    0.75
    0.25
    0.45
    0.19
    Basic EPS, GAAP
    -0.53
    -0.63
    -2.14
    -1.23
    -1.57
    -0.94
    -0.87
    Free Cash Flow per Basic Share
    -0.51
    -0.39
    -1.49
    0.13
    -1.53
    -0.73
    -1.18
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -0.74
    -1.32
    -3.67
    -4.03
    -5.47
    -6.38
    -7.09
    Tangible Book Value per Share
    0.32
    0.3
    5.99
    3.32
    1.92
    1.03
    0.47
    Basic Weighted Avg Shares
    18
    25
    20
    26
    27
    27
    27
    Sales/Revenue/Turnover
    - -
    4
    5
    19
    7
    12
    5
    Operating Margin (%)
    - -
    -391.59
    -815.2
    -179.66
    -641.07
    -247.81
    -591.7
    Depreciation Expense
    - -
    - -
    1
    1
    1
    - -
    - -
    Net Income, GAAP
    -10
    -16
    -42
    -32
    -42
    -25
    -23
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    -425.06
    -791.68
    -164.55
    -618.57
    -209.6
    -466.45
    Working Capital
    6
    11
    125
    119
    84
    61
    48
    LT Debt
    2
    4
    5
    - -
    - -
    - -
    - -
    Total Equity
    6
    8
    118
    86
    51
    28
    13
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    26
    26
    26
    Market Capitalization
    34
    35
    42

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'25
    Jun'25
    Sep'25
    Total Current Assets
    70
    60
    52
    Cash, Cash Equivalents & STI
    67
    56
    50
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    10
    6
    4
    Payables & Accruals
    8
    3
    2
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    274%
    -45.98%
    Free Cash Flow
    - -
    -249.27%
    -52.29%
    Net Income, GAAP
    - -
    39.38%
    -40.02%
    Sales/Revenue/Turnover
    - -
    - -
    77.01%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    1
    5
    - -
    - -
    7
    2024
    7
    - -
    - -
    5
    12
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.53
    -0.48
    -0.34
    - -
    -1.57
    2024
    -0.02
    -0.31
    -0.46
    -0.15
    -0.94
    2025
    -0.13
    -0.32
    -0.27
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      LAVA Therapeutics N.V. (NASDAQ:LVTX) Given Consensus Recommendation of “Reduce” by Analysts

    • defenseworld.net

      Brokerages Set LAVA Therapeutics N.V. (NASDAQ:LVTX) PT at $2.69

    • gurufocus.com

      Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact

    • globenewswire.com

      LAVA Announces Exceeding Minimum Condition in Tender Offer and Intent to Delist from Nasdaq

    • globenewswire.com

      LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

    • prnewswire.com

      Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

    • globenewswire.com

      LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

    • globenewswire.com

      LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    • prnewswire.com

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, LVTX, ENZB on Behalf of Shareholders

    • prnewswire.com

      SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)

    • businesswire.com

      LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders

    • globenewswire.com

      LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

    • globenewswire.com

      LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

    • globenewswire.com

      LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

    • benzinga.com

      Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

    • globenewswire.com

      LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

    • globenewswire.com

      LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

    • globenewswire.com

      LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

    • globenewswire.com

      LAVA Reports Second Quarter 2024 Financial Results and Business Update

    • 247wallst.com

      4 Stocks Under $5 To Buy Now